Related Experiment Videos

Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia

M J Schultz1, J Wijnholds, M P Peppelenbosch

  • 1Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.j.schultz@amc.uva.nl

Insights

Mice lacking multidrug resistance protein 1 (mrp1) showed increased resistance to pneumococcal pneumonia. This protection is linked to altered leukotriene metabolism, specifically higher levels of LTB(4), suggesting mrp1 as a therapeutic target.

Area of Science:

  • Immunology
  • Microbiology
  • Biochemistry

Background:

  • Leukotrienes (LTs) play a role in lung antibacterial defense.
  • Multidrug resistance protein 1 (mrp1) facilitates the cellular export of LTC(4).

Purpose of the Study:

  • To investigate the role of mrp1 in host defense against Streptococcus pneumoniae pneumonia.
  • To elucidate the mechanisms underlying mrp1's influence on lung immunity.

Main Methods:

  • Comparison of mrp1(-/-) and wild-type mice infected with Streptococcus pneumoniae.
  • Assessment of bacterial load, mortality, and leukotriene levels (LTC(4), LTB(4)).
  • Pharmacological inhibition of 5-lipoxygenase-activating protein and LTB(4) antagonism.

Main Results:

  • mrp1(-/-) mice exhibited reduced bacterial outgrowth and mortality compared to wild-type mice.
  • Survival in mrp1(-/-) mice was similar to wild-type mice when treated with a 5-lipoxygenase inhibitor.
  • Elevated LTB(4) levels in mrp1(-/-) mice correlated with their enhanced survival, which was abrogated by an LTB(4) antagonist.
  • In vitro studies indicated that intracellular LTC(4) accumulation in mrp1(-/-) cells inhibits LTC(4)-synthase, favoring LTB(4) production.

Conclusions:

  • mrp1 deficiency confers resistance to pneumococcal pneumonia through a mechanism involving increased LTB(4) release.
  • Altered leukotriene metabolism, specifically enhanced LTB(4) production, is key to this protective effect.
  • mrp1 represents a potential novel target for adjunctive therapies in pneumonia treatment.

Related Concept Videos